Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Mirabegron (Primary) ; Tamsulosin
- Indications Overactive bladder
- Focus Therapeutic Use
- 29 Dec 2021 Primary endpoint (The change from baseline to three months later after brachytherapy in mean volume voided per micturition) has not been met. according to the results published in the Urology.
- 29 Dec 2021 Results published in the Urology
- 08 Dec 2020 Status changed from recruiting to completed.